04.23.08
High Throughput Kinase Screening Expedites Drug Discovery and Development

02.28.08
Ambit Biosciences Announces the Formation of Two Clinical Advisory Boards

12.08.07
Ambit Biosciences Presents Data on AC220 in Acute Myeloid Leukemia at American Society for Hematology Conference

11.14.07
Ambit Biosciences Raises Over $49 Million In Series D Finanacing

10.31.07
Ambit Biosciences Announces Second Expansion of Collaboration with Bristol-Myers Squibb

08.13.07
Ambit Biosciences Announces Significant Enhancements to KinomeScan™ Profiling Technology

04.10.07
Ambit Biosciences Begins Dosing Patients in Phase I Clinical Trial of Lead Kinase Inhibitor AC220

04.03.07
Ambit Biosciences is First to Offer More Than Half the Human Kinome in its Kinase Profiling Panel

01.08.07
Ambit Biosciences Appoints Wendell Wierenga, Ph.D., as Executive Vice President of Research & Development

12.13.06
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board

12.05.06
Ambit Biosciences Appoints Kerry Kelly, J.D., as Vice President and General Counsel

12.04.06
World Economic Forum Announces Technology Pioneers 2007

11.06.06
Ambit Biosciences Announces Discovery and Development Collaboration with Cephalon, Inc. Focused on Kinase Inhibitors

03.07.06
Ambit Biosciences Adds Kinase Experts to Scientific Advisory Board and Expands Board of Directors

02.14.06
Ambit Biosciences Expands Kinase Profiling Panel to 234 Kinases, Plans 14X Increase in Profiling Capacity for 2006

01.26.06
Ambit Biosciences Appoints Donald R. Myll Senior Vice President Commercial Operations and Chief Financial Officer;
Stephen Keane Joins Ambit as Vice President, Corporate Development

01.16.06
Paper in Cancer Research Further Validates Ambit Biosciences' KinomeScan Kinase Profiling Platform

12.12.05
Ambit Expands Collaboration With Bristol-Myers Squibb Company, In-Licenses Kinase Inhibitor Program Targeting Solid Tumors

07.26.05
Ambit Biosciences Publishes Data Identifying Drug Candidates That Counter Resistance to Gleevec, Iressa and Tarceva

05.12.05
Ambit Biosciences Raises $31 Million in Series C Financing

03.03.05
Ambit Biosciences Expands Drug Discovery and Development Teams

02.14.05
Ambit Biosciences Publishes New Method and Results in Nature Biotechnology that May Lead to New Uses for Drugs Such as Gleevec and Improved Drug Discovery and Development

01.17.05
Ambit Biosciences Announces Drug Screening Collaboration with Bristol-Myers Squibb

01.17.05
Ambit Biosciences Announces Drug Screening Collaboration with GlaxoSmithKline

01.17.05
Ambit Biosciences Announces Compound Profiling Collaboration with Pfizer